151 related articles for article (PubMed ID: 24413373)
41. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
[TBL] [Abstract][Full Text] [Related]
42. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Ermer J; Corcoran M; Lasseter K; Marbury T; Yan B; Martin PT
Ther Drug Monit; 2016 Aug; 38(4):546-55. PubMed ID: 26926668
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
44. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
Fukumura K; Yamada T; Yokota T; Kawasaki A
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
[TBL] [Abstract][Full Text] [Related]
45. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol.
Bui K; She F; Sostek M
J Clin Pharmacol; 2014 Dec; 54(12):1375-82. PubMed ID: 24946021
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study.
David OJ; Pryce M; Meiser K; Picard F; Emotte C; Kobalava Z; Moiseev V; Schmouder R
Int J Clin Pharmacol Ther; 2015 Oct; 53(10):847-54. PubMed ID: 26308173
[TBL] [Abstract][Full Text] [Related]
47. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.
Soe LH; Wurz GT; Kao CJ; Degregorio MW
Int J Womens Health; 2013 Sep; 5():605-11. PubMed ID: 24109197
[TBL] [Abstract][Full Text] [Related]
48. Effects of Renal Impairment and Hepatic Impairment on the Pharmacokinetics of Hydrocodone After Administration of a Hydrocodone Extended-Release Tablet Formulated With Abuse-Deterrence Technology.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):141-9. PubMed ID: 27138027
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment.
Sidharta PN; Lindegger N; Ulč I; Dingemanse J
J Clin Pharmacol; 2014 Mar; 54(3):291-300. PubMed ID: 24122797
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function.
Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
Br J Clin Pharmacol; 2022 Jan; 88(1):237-247. PubMed ID: 34169560
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
52. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
53. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
[TBL] [Abstract][Full Text] [Related]
54. Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib.
Nguyen L; Holland J; Ramies D; Mamelok R; Benrimoh N; Ciric S; Marbury T; Preston RA; Heuman DM; Gavis E; Lacy S
J Clin Pharmacol; 2016 Sep; 56(9):1130-40. PubMed ID: 26865195
[TBL] [Abstract][Full Text] [Related]
55. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
[TBL] [Abstract][Full Text] [Related]
56. Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor.
Mita S; Meyers D; Pal P; Lin T; Majumdar T; Rebello S; Sunkara G; Chen J
Clin Pharmacokinet; 2015 Jul; 54(7):751-60. PubMed ID: 25627776
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and Tolerability of Lorcaserin in Special Populations: Elderly Patients and Patients with Renal or Hepatic Impairment.
Christopher RJ; Morgan ME; Tang Y; Anderson C; Sanchez M; Shanahan W
Clin Ther; 2017 Apr; 39(4):837-848.e7. PubMed ID: 28365033
[TBL] [Abstract][Full Text] [Related]
60. Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
Liu Y; Zhou S; Assaf M; Nissel J; Palmisano M
Clin Pharmacol Drug Dev; 2016 Nov; 5(6):469-479. PubMed ID: 27870479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
